Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) FCF Margin (2016 - 2022)

Aptevo Therapeutics' FCF Margin history spans 8 years, with the latest figure at 164.32% for Q1 2022.

  • For Q1 2022, FCF Margin rose 15352.0% year-over-year to 164.32%; the TTM value through Dec 2022 reached 675.21%, down 49304.0%, while the annual FY2022 figure was 676.01%, 49384.0% down from the prior year.
  • FCF Margin for Q1 2022 was 164.32% at Aptevo Therapeutics, down from 109.09% in the prior quarter.
  • Across five years, FCF Margin topped out at 56.47% in Q4 2019 and bottomed at 979.49% in Q2 2020.
  • The 5-year median for FCF Margin is 215.91% (2019), against an average of 328.52%.
  • The largest annual shift saw FCF Margin crashed -76358bps in 2020 before it soared 80444bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 773.64% in 2018, then soared by 93bps to 56.47% in 2019, then crashed by -357bps to 258.03% in 2020, then skyrocketed by 58bps to 109.09% in 2021, then plummeted by -51bps to 164.32% in 2022.
  • Per Business Quant, the three most recent readings for APVO's FCF Margin are 164.32% (Q1 2022), 109.09% (Q4 2021), and 169.74% (Q3 2021).